Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Snape

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
Plos One|November 5, 2016
Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly AdultsRajeka Lazarus, Sarah Kelly, Matthew D Snape, et al.
The Journal of Clinical Investigation|April 22, 2020
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responsesHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Pediatric Infectious Disease Journal|May 8, 2024
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory StudyAlexander Maytum, David Porter, Philip de Whalley, et al.
The Pediatric Infectious Disease Journal|June 16, 2011
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccinePhilip C S de Whalley, Matthew D Snape, Dominic F Kelly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2010
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancyJamie Findlow, Ray Borrow, Matthew D Snape, et al.
Human Vaccines & Immunotherapeutics|September 15, 2025
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 monthsSabine Schnyder Ghamloush, Sue Fanning, Brandon Essink, et al.
The Journal of Infectious Diseases|April 21, 2019
Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United KingdomRama Kandasamy, Merryn Voysey, Sarah Collins, et al.
The Pediatric Infectious Disease Journal|November 13, 2018
Determinants of Influenza and Pertussis Vaccination Uptake in Pregnancy: A Multicenter Questionnaire Study of Pregnant Women and Healthcare ProfessionalsChristopher R Wilcox, Anna Calvert, Jane Metz, et al.
Vaccine|December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trialMildred A Iro, Matthew D Snape, Merryn Voysey, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 18, 2017
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedulesManish Sadarangani, Tim Sell, Mildred A Iro, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Plos One|November 5, 2016
Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly AdultsRajeka Lazarus, Sarah Kelly, Matthew D Snape, et al.
The Journal of Clinical Investigation|April 22, 2020
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responsesHelen R Wagstaffe, Elizabeth A Clutterbuck, Viki Bockstal, et al.
The Pediatric Infectious Disease Journal|May 8, 2024
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory StudyAlexander Maytum, David Porter, Philip de Whalley, et al.
The Pediatric Infectious Disease Journal|June 16, 2011
Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccinePhilip C S de Whalley, Matthew D Snape, Dominic F Kelly, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 20, 2010
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancyJamie Findlow, Ray Borrow, Matthew D Snape, et al.
Human Vaccines & Immunotherapeutics|September 15, 2025
Safety and immunogenicity of an mRNA-based RSV vaccine in seropositive children aged 12-59 monthsSabine Schnyder Ghamloush, Sue Fanning, Brandon Essink, et al.
The Journal of Infectious Diseases|April 21, 2019
Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United KingdomRama Kandasamy, Merryn Voysey, Sarah Collins, et al.
The Pediatric Infectious Disease Journal|November 13, 2018
Determinants of Influenza and Pertussis Vaccination Uptake in Pregnancy: A Multicenter Questionnaire Study of Pregnant Women and Healthcare ProfessionalsChristopher R Wilcox, Anna Calvert, Jane Metz, et al.
Vaccine|December 5, 2016
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trialMildred A Iro, Matthew D Snape, Merryn Voysey, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|October 18, 2017
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedulesManish Sadarangani, Tim Sell, Mildred A Iro, et al.
Pageof 17